Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BARR GENERIC WARFARIN TO BE LAUNCHED IN SUMMER; DUPONT MERCK CONTINUES EFFORTS TO PASS STATE LAWS REQUIRING PHYSICIAN APPROVAL FOR NTI SUBSTITUTION

Executive Summary

Barr intends to launch its generic version of warfarin during the summer, the company said following FDA's March 26 approval of the first generic version of DuPont Merck's anticoagulant Coumadin.

You may also be interested in...



FDA Approves Generic Of GSK Flonase But Launch Halted By Restraining Order

FDA's approval of generic Flonase has prompted a lawsuit by GlaxoSmithKline representing another challenge by brand manufacturers to the legitimacy of FDA-approved generic drugs

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel